BioCentury
ARTICLE | Company News

Roche, ICN in HCV deal

July 2, 2001 7:00 AM UTC

ICN Pharmaceuticals (ICN) granted Roche (SWX:ROCZ) a license to its Levovirin L-isomer ribavirin, which is in Phase I testing to treat hepatitis C virus. Under the agreement, ROCZ will have worldwide ...